[Oxatomide: review of pharmacodynamic effects and clinical effects in dermatology].
Oxatomide is a new anti-allergy drug, derived from benzamidazole, which has shown original pharmacological properties at different stages of the degranulation of mastocytes and basophils, inhibition of the increase of intracellular calcium, inhibition of histamine release and of the synthesis of leukotrienes and prostaglandins. In addition, it has an antagonistic action on the histamine H1 receptors and inhibits the effects of serotonin and SRSA leukotrienes. Clinical trials have shown the clinical efficacy of oxatomide on chronic urticaria and atopic dermatitis, double blind against placebo. Also its action is quicker than certain reference molecules with which it was compared. The product seems to have excellent tolerance. Oxatomide is a molecule of which the pharmacological properties are coupled with clinical efficacy on allergic dermatoses.
Clinique des Maladies Cutanées, Hôpital St-Louis.
P P
PP
Cabotin
M
M
Janier
D000818:Animals; D001491:Basophils / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D015550:Cell Degranulation / Q000187:drug effects; D003872:Dermatitis / Q000188:drug therapy* / Q000276:immunology; D004285:Dogs; D006634:Histamine H1 Antagonists; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D008407:Mast Cells / Q000187:drug effects; D010879:Piperazines / Q000627:therapeutic use*; D051381:Rats; D011968:Receptors, Histamine / Q000187:drug effects; D013189:SRS-A / Q000378:metabolism; D012702:Serotonin Antagonists
D006634:Histamine H1 Antagonists; D010879:Piperazines; D011968:Receptors, Histamine; D013189:SRS-A; D012702:Serotonin Antagonists; C015408:oxatomide; D002118:Calcium
Oxatomide: revue des effets pharmacodynamiques et des effets cliniques en dermatologie.